Chief Ethics, Risk & Compliance Officer of Novartis since 2018
Klaus Moosmayer joined Novartis in 2018 as Chief Ethics, Risk & Compliance Officer and a member of the Executive Committee. He was previously chief compliance officer at Siemens AG, where he spent 18 years in roles of increasing seniority. He began his career as a lawyer in Germany, specializing in white-collar crime, business law and litigation.
Today, Klaus is transforming ethics, risk and compliance at Novartis in the same way the company is reimagining medicine – by pursuing innovation, using data and digital, and unleashing the creative power of employees to embed ethics into the core of the business.
"Doing what’s right for patients and society is, and must always be, our priority. It’s a journey, and we remain humble in our understanding that this will take time. But we are well on our way."
Klaus led the launch of a new Code of Ethics in 2020, based on crowdsourced feedback from employees and on behavioral science. He introduced new integrated risk and compliance management systems and related digital platforms that help senior management and employees prioritize and manage risks in an increasingly complex regulatory landscape. And he set up a new process to ensure human rights are further integrated into core business practices, especially external partner risk management.
Klaus brings a global reputation as a leader in the field of ethics and compliance. He was the first head of compliance from a company to be invited to address the General Assembly of the United Nations about the fight against corruption. He represents business in global integrity, governance, compliance and anti-corruption platforms at the Organisation for Economic Co-operation and Development (OECD), G20/B20, World Economic Forum (WEF) and other organizations.
As a believer in collaboration, Klaus co-founded and chaired a nonprofit association of compliance heads from major European companies and is driving collective action efforts to foster joint integrity standards within the pharmaceutical industry and beyond.